Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
Todayâs edition is brought to you by Pacaso and 1440 Media, whose support helps us deliver independent policy intelligence to your inbox.
Nebraskaâs cannabis commission surrendered to Governor Pillenâs demand for strict plant caps, putting program survival ahead of patient access. Massachusetts regulators fielded fierce criticism on social consumption rules as their medical program consolidates, New York unlocked new dispensary real estate, and federal courts chipped away at prohibition-era defenses. Meanwhile, NIH data confirmed cannabis reduces alcohol use among heavy drinkers, Oklahomaâs trucking shortage worsened under THC testing rules, and Mike Tyson suddenly emerged as a messenger on rescheduling.
đ˝ Nebraskaâs plant cap showdown
â Massachusetts cafĂŠ backlash
đĽ Tyson teases rescheduling
Stay sharp. Read what matters.
How 433 Investors Unlocked 400X Return Potential
Institutional investors back startups to unlock outsized returns. Regular investors have to wait. But not anymore. Thanks to regulatory updates, some companies are doing things differently.
Take Revolut. In 2016, 433 regular people invested an average of $2,730. Today? They got a 400X buyout offer from the company, as Revolutâs valuation increased 89,900% in the same timeframe.
Founded by a former Zillow exec, Pacasoâs co-ownership tech reshapes the $1.3T vacation home market. Theyâve earned $110M+ in gross profit to date, including 41% YoY growth in 2024 alone. They even reserved the Nasdaq ticker PCSO.
The same institutional investors behind Uber, Venmo, and eBay backed Pacaso. And you can join them. But not for long. Pacasoâs investment opportunity ends September 18.
Paid advertisement for Pacasoâs Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.